TT-00973
/ TransThera Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 23, 2025
Phase 1 study of TT-00973-MS' a highly selective and potent AXL inhibitor' in patients with advanced solid tumors.
(ASCO 2025)
- P1 | "The preliminary findings from this phase I study demonstrated that the AXL inhibitor TT-00973-MS monotherapy exhibits a well-tolerable safety profile, promising pharmacodynamic activity, with early signs of efficacy in pts with heavily pre-treated advanced solid tumors. Further studies are warranted to comprehensively evaluate the efficacy and safety of TT-00973-MS in large patient populations and specific tumor types. Clinical trial information: NCT05673538"
Clinical • IO biomarker • Metastases • P1 data • Dyslipidemia • Hypertriglyceridemia • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Renal Disease • Solid Tumor • GAS6
January 06, 2023
TT-00973-MS Tablets in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: TransThera Sciences (Nanjing), Inc.
Metastases • New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1